Hepatotoxicity of Antituberculosis Therapy (HAT) Study
Launched by HUASHAN HOSPITAL · Nov 7, 2019
Trial Information
Current as of July 07, 2025
Unknown status
Keywords
ClinConnect Summary
Drug-induced liver injury (DILI) is a common side effect in antituberculosis therapy, which interuputs the treatment of TB and leads to a higher proportion of Multidrug-Resistence TB(MDR-TB).The study primalily aims to observe the proportion of DILI in antituberculosis therapy. Furthermore, the secondary objective is to study the proportion of liver injury of based liver disase,liver failure and adjustment of chemotherapy in the obersevational study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1) Patients who are about to start anti-tuberculosis treatment 2) Male or female, age \> 18 years old 3) Voluntary signing of "Subject Informed Consent Form"
- Exclusion Criteria:
- • - 1)A history of taking anti-tuberculosis drugs within 6 months before the treatment; 2)Abnormal liver function before starting anti-tuberculosis treatment; 3)DILI at the time of enrollment. 4)Combined with malignant tumors (including hematological tumors), HIV infection, etc.
- • 5) According to the investigator's judgment, patients who cannot complete this study or who cannot comply with the requirements of this study.
About Huashan Hospital
Huashan Hospital, affiliated with Fudan University in Shanghai, is a leading medical institution renowned for its commitment to innovative research and high-quality patient care. As a prominent clinical trial sponsor, Huashan Hospital leverages its extensive expertise in various medical disciplines to advance the development of new therapies and treatment modalities. The hospital's state-of-the-art facilities and multidisciplinary teams facilitate rigorous clinical investigations, ensuring adherence to ethical standards and regulatory compliance. With a focus on improving patient outcomes, Huashan Hospital actively collaborates with academic and industry partners to drive forward-thinking research initiatives that address critical healthcare challenges.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Wenhong Zhang
Study Chair
Huashan Hospital
Yongguo LI
Principal Investigator
First Affiliated Hospital of Harbin Medical University
Dapeng Bai
Principal Investigator
Haihe Hospital in Tianjin
Meiying Wu
Principal Investigator
The Fifth Hospital in Suzhou
Huaicheng Wang
Principal Investigator
Third People's Hospital in Changzhou
Qinfang Ou
Principal Investigator
Fifth Hospital in Wuxi
Yonglan Pu
Principal Investigator
First People's Hospital in Taicang
Fan Xia
Principal Investigator
The 905th Hospital of the PLA Navy
Yuanyuan Chen
Principal Investigator
Red Cross Hospital, Hangzhou, China
Zumo Zhou
Principal Investigator
People's Hospital in Zhuji
Xiaohong Chen
Principal Investigator
Fuzhou Pulmonary Hospital in Fujian
Guofang Deng
Principal Investigator
The Third People's Hospital in Shenzhen
Shiwu Ma
Principal Investigator
People's Liberation Army Joint Service Support Unit 920 Hospital (formerly Kunming General Hospital of Chengdu Military Region)
Youfang Gao
Principal Investigator
People's Hospital in Haozhou
Yongfang Jiang
Principal Investigator
Central South University Xiangya Second Hospital
Hongying Yu
Principal Investigator
Huaihua First People Hospital in Hunan
Bo Chen
Principal Investigator
Longtan Hospital in Guangxi
Weiqiang Zheng
Principal Investigator
Guangdong Medical University Affiliated Hospital
Liyuan Zhang
Principal Investigator
The Second Affiliated Hospital of Hainan Medical College
Guanghui Xu
Principal Investigator
Tuberculosis Control Center in Jiangmen
Anjie Zhang
Principal Investigator
Yubei Second People's Hospital
Hancheng Liang
Principal Investigator
The Sixth People's Hospital in Dongguan
Yuqing Wu
Principal Investigator
Chest Hospital in Jiangxi
Xilin Zhang
Principal Investigator
The Forth People's Hospital in Foshan
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials